抗肝纤维化中成药预防酒精性肝病相关肾功能减退的疗效评价

孟培培; 刘尧; 周梅月; 于浩; 杨玉英; 江宇泳

doi:10.3969/j.issn.1001-5256.2020.09.024

抗肝纤维化中成药预防酒精性肝病相关肾功能减退的疗效评价

DOI: 10.3969/j.issn.1001-5256.2020.09.024

1. 首都医科大学附属北京地坛医院中西医结合中心
2. 北京中医药大学东直门医院

基金项目:

首都卫生科研发展专项(首发2020-2-2172)；北京中医药科技基金(JJ2018-44)；十三五科技重大专项(2018ZX10725505-001)；

详细信息

中图分类号: R259
计量
- 文章访问数: 1150
- HTML全文浏览量: 55
- PDF下载量: 113
- 被引次数: 0
出版历程
- 收稿日期: 2020-03-14
- 出版日期: 2020-09-20

Effect of anti-liver fibrosis Chinese patent drugs in preventing renal hypofunction associated with alcoholic liver disease

Department of Integrative Medicine,Beijing Ditan Hospital,Capital Medical University
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Research funding:

摘要

摘要: 目的探讨抗肝纤维化中成药对于酒精性肝病（ALD）相关肾功能减退的影响。方法回顾性收集首都医科大学附属北京地坛医院2008年8月1日-2016年3月1日收治的ALD住院患者592例,根据应用扶正化瘀胶囊、安络化纤丸或复方鳖甲软肝片是否≥180累计日剂量分为中药组及对照组,对入组患者进行1∶1倾向评分匹配,得到两组患者各187例,记录病史、饮酒量、血常规、肝肾功能、凝血机制和腹部影像学等结果。符合正态分布的计量资料两组间比较采用t检验,非正态分布采用Mann-Whitney U检验,计数资料两组间比较采用χ2检验,Kalplan-Merier法比较两组患者肾功能减退累积发生率。结果两组患者年龄、饮酒量、合并高血压、糖尿病比例、基线AST、估算肾小球滤过率（eGFR）、尿酸、凝血酶原时间均无显著性差异（P值均> 0.05）,随访时间36（23～54）个月。尿酸（HR=1.003,95%CI:1.001～1.005,P=0.001）、凝血酶原时间（HR=1.103,95%CI:1.034～1.177,P=0.003）和红细胞体积分布宽度（HR=1.024,95%CI:1.011～1.03...
- 肝疾病,酒精性 /
- 肾功能不全 /
- 中成药
Abstract: Objective To investigate the effect of anti-liver fibrosis Chinese patent drugs on renal hypofunction associated with alcoholic liver disease( ALD). Methods A retrospective analysis was performed for 592 patients with ALD who were admitted to Beijing Ditan Hospital,Capital Medical University,from August 1,2008 to March 1,2016,and according to whether they were treated with Fuzheng Huayu capsules,Anluo Huaxian pills,or Fufang Biejia Ruangan tablets for ≥180 cumulative defined daily doses,they were divided into Chinese medicine group and control group. After propensity score matching at a ratio of 1 ∶ 1,two groups were obtained with 187 patients in each group. Related data were recorded,including medical history,drinking amount,routine blood test results,liver and renal function,coagulation,and abdominal imaging findings. The t-test was used for comparison of normally distributed continuous data between groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups; the Kaplan-Meier method was used to compare the cumulative incidence rate of renal hypofunction between two groups. Results There were no significant differences between the two groups in age,drinking amount,proportion of patients with hypertension or diabetes,baseline aspartate aminotransferase,estimated glomerular filtration rate,uric acid,and prothrombin time,and the patients were followed up for 36 months( range 23-54 months). Uric acid( hazard ratio [HR]= 1. 003,95% confidence interval [CI]: 1. 001-1. 005,P = 0. 001),prothrombin time( HR = 1. 103,95% CI: 1. 034-1. 177,P = 0. 003),and red cell volume distribution width( HR = 1. 024,95% CI: 1. 011-1. 038,P < 0. 001) were independent risk factors for renal hypofunction in patients with ALD,and anti-liver fibrosis Chinese patent drug was an independent protective factor against renal hypofunction( HR = 0. 170,95% CI: 0. 053-0. 552,P = 0. 003). The Chinese medicine group had a significantly lower incidence rate of renal hypofunction than the control group( 16. 6 % vs 32. 1 %,χ2= 10. 263,P = 0. 001). The subgroup analysis of the patients in the Chinese medicine group showed that Chinese medicine treatment for > 24 months had the best effect( HR = 0. 210,95 % CI: 0. 084-0. 525,P = 0. 001). Compared with the control group,the Chinese medicine group had a significantly longer time to the onset of renal hypofunction( 36 months vs24 months,Z =-2. 652,P = 0. 008). Conclusion Anti-liver fibrosis Chinese patent drugs can reduce the incidence rate and delay the onset of renal hypofunction in patients with ALD.
- liver diseases,alcoholic /
- renal insufficiency /
- CHINESE PATENT DRUGS

HTML全文

参考文献(16)

[1] GBD 2016 Alcohol Collaborators. Alcohol use and burden for195 countries and territories,1990-2016:A systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet,2018,392(10152):1015-1035.

[2] KAARTINEN K,NIEMELA O,SYRJANEN J,et al. Alcohol consumption and kidney function in IgA glomerulonephritis[J].Nephron Clin Pract,2009,112(2):c86-c93.

[3] YIN XX,YIN CJ. Discussion on the rule of Chinese Medicine in the treatment of alcoholic liver disease[J]. Chin J Exp Med Formul,2011,17(12):285-287.(in Chinese)殷晓轩，尹常健．酒精性肝病中医用药规律探讨[J]．中国实验方剂学杂志，2011,17(12):285-287.

[4] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):939-946.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组．酒精性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):939-946.

[5] World Health Organisation Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs[EB/OL].(2019-12-16)[2020-03-14]. http://www. whocc.no/atc_ddd_publications/atc_ddd_index/．

[6] XIANG YX,LOU HY. Treatment of Anluohuaxianwan on alcoholic fatty liver in rats[J]. Chin J Biological Pharms,2011,32(6):440-443.(in Chinese)相妍笑，娄海燕．安络化纤丸对大鼠酒精性脂肪肝的治疗作用[J]．中国生化药物杂志，2011,32(6):440-443.

[7] LI YL,WANG XM. Treatment of 66 cases of alcoholic liver disease with Anluohuaxianwan[J]. Pract Clin J Intergr Tradit Chin Western Med,2010,10(1):15-16.(in Chinese)李艳丽，王雪梅．安络化纤丸治疗酒精性肝病66例[J]．实用中西医结合临床，2010,10(1):15-16.

[8] LI FY,SUN JH,TIAN DL,et al. Experimental research on Fufangbiejiaruangan inhibiting alcoholic hepatic fibrosis in rats[J]. Infect Dis Info,2008,21(6):365-368.(in Chinese)李丰衣，孙劲晖，田德禄，等．复方鳖甲软肝片抑制大鼠酒精性肝纤维化的实验研究[J]．传染病信息，2008,21(6):365-368.

[9] LI Y,KE WB,CHENG D. Efficacy of Fuzhenghuayu capsule combined with adenosylmethionine in the treatment of patients with alcoholic cirrhosis[J]. China Med Herald,2016,13(28):91-94.(in Chinese)李亚，柯文炳，程丹．扶正化瘀胶囊联合腺苷蛋氨酸治疗酒精性肝硬化的效果[J]．中国医药导报，2016,13(28):91-94.

[10] ZHENG JS,LI JX,YUN XY. Therapeutic effects of Fuzhenghuayu capsule combined with polyene phosphatidylcholine capsule on patients with alcoholic cirrhosis[J]. Chronic Pathematology J,2019,20(8):1204-1206.(in Chinese)郑锦顺，李加学，云晓焱．扶正化瘀胶囊联合多烯磷脂酰胆碱胶囊治疗酒精性肝硬化疗效观察[J]．慢性病学杂志，2019,20(8):1204-1206.

[11] di PASCOLI M,ZAMPIERI F,VERARDO A,et al. Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation[J]. Hepatology,2016,64(3):923-930.

[12] PENG YS,HAN KQ,RUAN X,et al. Expression of p53,TGF-β1and inflammatory cytokines in a novel alcoholic kidney injury mouse model[J]. Current Immun,2019,39(5):378-383.(in Chinese)彭月霜，韩可琪，阮昕，等．p53、TGF-β1及炎性细胞因子在新型酒精性肾损伤小鼠模型中的表达[J]．现代免疫学，2019,39(5):378-383.

[13] XIONG Y,LIU ZZ,LI YJ,et al. Prevention and treatment value of compound Biejiaruangan troche in mice renal fibrosis[J]. J Guizhou Med Univ,2019,44(2):163-168.(in Chinese)熊英，刘宗泽，李佑敬，等．复方鳖甲软肝片对小鼠肾纤维化的防治作用[J]．贵州医科大学学报，2019,44(2):163-168.

[14] SHEN WZ,XIE ZW,CAI JX,et al. Effect of complex Biejia Ruangan tablet on renal TGF-β1 expression in rats model with chronic renal failure[J]. Chin J Integ Trad Western Nephrol,2006,7(10):570-573.(in Chinese)沈维增，谢峥伟，蔡军红，等．复方鳖甲软肝片对慢性肾衰竭大鼠肾组织TGF-β1表达的影响[J]．中国中西医结合肾病杂志，2006,7(10):570-573.

[15] SHAO Y,ZHAO ZJ,YANG MJ. Experimental study on effects of compond Biejia Ruangan tablets on fibronectin in 5/6 nephrectomize rats[J]. J Shandong Univ Tradit Chin Med,2005,29(3):240-242.(in Chinese)邵悦，赵宗江，杨美娟．复方鳖甲软肝片对5/6肾切除大鼠肾组织FN表达的影响[J]．山东中医药大学学报，2005,29(3):240-242.

[16] LI XD. Effect of Fuzheng Huayu capsule combined with Entecavir on patients with chronic hepatitis B on liver fibrosis,T lymphocyte subsets and renal function[J]. Hebei Med J,2016,38(14):2158-2160.(in Chinese)李学冬．扶正化瘀胶囊联合恩替卡韦治疗慢性乙型肝炎对患者肝纤维化、T淋巴细胞亚群、肾功能的影响及疗效评价[J]．河北医药，2016,38(14):2158-2160.

施引文献

资源附件(0)

访问统计